RT Journal Article SR Electronic T1 Biallelic truncation variants in ATP9A are associated with a novel autosomal recessive neurodevelopmental disorder JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.31.21257832 DO 10.1101/2021.05.31.21257832 A1 Mattioli, Francesca A1 Darvish, Hossein A1 Paracha, Sohail Aziz A1 Tafakhori, Abbas A1 Firouzabadi, Saghar Ghasemi A1 Chapi, Marjan A1 Azhar Baig, Hafiz Muhammad A1 Reymond, Alexandre A1 Antonarakis, Stylianos E. A1 Ansar, Muhammad YR 2021 UL http://medrxiv.org/content/early/2021/06/04/2021.05.31.21257832.abstract AB Intellectual disability (ID) is a highly heterogeneous disorder with hundreds of associated genes. Despite progress in the identification of the genetic causes of ID following the introduction of high-throughput sequencing, about half of affected individuals still remain without a molecular diagnosis. Consanguineous families with affected individuals provide a unique opportunity to identify novel recessive causative genes.In this report we describe a novel autosomal recessive neurodevelopmental disorder. We identified two consanguineous families with homozygous variants predicted to alter the splicing of ATP9A which encodes a transmembrane lipid flippase of the class II P4-ATPases. The three individuals homozygous for these putatively truncating variants presented with severe ID, motor and speech impairment, and behavioral anomalies. Consistent with a causative role of ATP9A in these patients, a previously described Atp9a-/-mouse model showed behavioral changes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Swiss National Science Foundation (31003A_182632) and the Lejeune Foundation (JLF #1838) to AR and the Childcare Foundation to SEA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study was approved by the IRBs of the Khyber Medical University, Peshawar, Pakistan, and the University Hospitals of Geneva, Switzerland (Protocol number: CER 11-036). Informed consent forms were obtained from guardians of all affected individuals who participated in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon request.